Fibrosis: Translation of Basic Research to Human Disease and Novel Therapeutics
Organizer(s): Paul W. Noble, Shelia M. Violette and Scott L. FriedmanDate: March 30 - April 04, 2012
Location: Big Sky Resort, Big Sky, MT, USA
Fibrosis is a pathological process in which diseased tissue is replaced with excess extracellular matrix ultimately leading to organ scarring and failure, a final common pathway in many forms of chronic disease affecting multiple tissues. Currently, there are minimal and inadequate treatment options for fibrotic disease. There is an urgent need to understand the cellular, molecular and genetic basis of fibrosis in humans and develop animal models that replicate and illuminate this pathological process. There is also a need to identify prognostic markers of disease susceptibility, biomarkers of disease progression and improved technologies to monitor the effectiveness of new therapies. The goal of the Keystone Symposia meeting on Fibrosis: Translation of Basic Research to Human Disease and Novel Therapeutics is to bring together researchers and clinicians in academia and industry to provide an integrated perspective of basic disease mechanisms, and to address the more pragmatic challenges associated with executing clinical trials and refining approaches to accelerate the clinical development of anti-fibrotic drugs.
Scholarship Deadline: November 30 2011
Discounted Abstract Deadline: November 30 2011
Abstract Deadline: January 5 2012
Discounted Registration Deadline: January 30 2012
We gratefully acknowledge additional support for this conference from:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Bristol-Myers Squibb Company
We gratefully acknowledge the generous grant for this conference provided by:National Heart, Lung, and Blood Institute (NHLBI)
Grant No. 1R13HL112456-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.